Asset Details
Do you wish to reserve the book?
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients
Do you wish to request the book?
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients
2011
Overview
In breast cancer, the prognostic impact of COX2 expression varies widely between studies. We examined the prognostic value of COX2 expression in a large cohort of breast cancer patients treated with primary surgery between 1985 and 1994 and explained the variable results of COX2 expression found in the literature. A tissue microarray was constructed of available tumour material, and ER, PgR, HER2, Ki67 and COX2 were examined by immunohistochemistry. Median follow-up was 19 years. Fifty-five percent (n = 369/677) of patients received no systemic treatment. COX2 was scored using a weighted histoscore. Analysis of COX2 expression in two groups based on the median (148; below vs. above) showed an increased hazard ratio (HR) of 1.35 (95% CI 1.05-1.75, P = 0.021) for disease-free survival (DFS) and of 1.39 (95% CI 1.03-1.82, P = 0.016) for overall survival (OS). However, COX2 did not remain independent in multivariate analysis. In patients with hormone receptor positive tumours, COX2 expression had a negative influence on outcome (low vs. high: DFS: HR 1.37, 95% CI 1.07-1.76, P = 0.013). This effect disappeared when endocrine therapy was administered (low vs. high: DFS: HR 0.93, 95% CI 0.51-1.70, P = 0.811) while it remained statistically significant when endocrine therapy was omitted (low vs. high: DFS: HR 1.48, 95% CI 1.12-1.94, P = 0.005). Our results show that COX2 plays a role in hormonal pathways. Our results can explain the results found in previously published studies.
Publisher
Boston : Springer US,Springer US,Springer,Springer Nature B.V,Springer Verlag
Subject
/ Aged
/ Analysis
/ Biological and medical sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - enzymology
/ Cancer
/ COX2
/ Cyclooxygenase 2 - biosynthesis
/ Female
/ Gene Expression Regulation, Enzymologic
/ Gene Expression Regulation, Neoplastic
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Immunohistochemistry - methods
/ Medicine
/ Oligonucleotide Array Sequence Analysis
/ Oncology
/ Prognostic and predictive factors
/ Tumors
